Kempner Capital Management Inc. Purchases 13,349 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Kempner Capital Management Inc. lifted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 50.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,600 shares of the medical equipment provider’s stock after buying an additional 13,349 shares during the quarter. Zimmer Biomet makes up about 2.3% of Kempner Capital Management Inc.’s holdings, making the stock its 23rd biggest holding. Kempner Capital Management Inc.’s holdings in Zimmer Biomet were worth $4,183,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in ZBH. Dunhill Financial LLC lifted its holdings in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC purchased a new stake in Zimmer Biomet during the 3rd quarter valued at $28,000. Bangor Savings Bank bought a new position in shares of Zimmer Biomet during the 3rd quarter valued at $31,000. Brooklyn Investment Group bought a new stake in shares of Zimmer Biomet in the third quarter worth $35,000. Finally, Quarry LP purchased a new position in Zimmer Biomet in the second quarter worth about $53,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Price Performance

ZBH opened at $110.63 on Friday. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The business has a fifty day moving average of $107.91 and a 200 day moving average of $108.22. Zimmer Biomet Holdings, Inc. has a 52-week low of $100.67 and a 52-week high of $133.90. The stock has a market cap of $22.02 billion, a P/E ratio of 21.03, a PEG ratio of 1.90 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting the consensus estimate of $1.74. The company had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm’s revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.65 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet’s payout ratio is 18.25%.

Analyst Ratings Changes

A number of research firms have commented on ZBH. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday. Wells Fargo & Company upped their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Stifel Nicolaus boosted their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Raymond James dropped their target price on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Finally, Barclays reduced their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a report on Thursday, December 12th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $124.11.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.